Company intelligence / Profile preview

Clearmind Biomedical

San Jose, California, United Statesclearmindbiomedicalgroup.com ↗

Ownership: Private
Employees: ~25
Development stage: Commercial

Overview

Clearmind Biomedical has developed the Axonpen System and Neuroblade System—micro-invasive neurosurgical devices for the removal of brain hemorrhages. The company successfully completed a first-in-human clinical trial demonstrating safety and efficacy in minimally invasive ICH surgery. The Axonpen System enables single-surgeon operations within one hour, aiming to improve outcomes and accessibility for ICH patients. FDA clearance was obtained for the Neuroblade System in August 2024.

Therapeutic areas: Neurology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships disclosed.

Beyond the preview

Go deeper on Clearmind Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clearmind Biomedical.

Explore the full profile